These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2370300)

  • 1. Relevance of biological properties of progestogen of oral contraceptives in treatment of androgen excess symptoms.
    Pang S
    J Clin Endocrinol Metab; 1990 Jul; 71(1):5-7. PubMed ID: 2370300
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns of oral contraceptive use in the United Kingdom.
    Vessey MP; Thorogood M
    Br J Rheumatol; 1989; 28 Suppl 1():46-7. PubMed ID: 2819354
    [No Abstract]   [Full Text] [Related]  

  • 3. Patterns of oral contraceptive use in the United States.
    Annegers JF
    Br J Rheumatol; 1989; 28 Suppl 1():48-50. PubMed ID: 2819355
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recommendations of the 4th Work Meeting of the Discussion Group of Zürich].
    Zentralbl Gynakol; 1990; 112(8):517-9. PubMed ID: 2363321
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experimental use of the new generation of Tri-Step contraceptive agents in 20 treated cases].
    Spasojević M
    Med Arh; 1984; 38(2):83-4. PubMed ID: 6444082
    [No Abstract]   [Full Text] [Related]  

  • 6. [Forms of hormonal contraception].
    Rothe K
    Z Arztl Fortbild (Jena); 1990; 84(1-2):13-9. PubMed ID: 2184591
    [No Abstract]   [Full Text] [Related]  

  • 7. [How to choose a contraceptive pill that suits?].
    Kivijärvi A
    Duodecim; 1997; 113(12):1169-73. PubMed ID: 11466847
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of the ratio of levonorgestrel, 0.15 mg, to ethinyl estradiol, 0.03 mg.
    Christie T
    J Reprod Med; 1983 Jan; 28(1 Suppl):63-5. PubMed ID: 6403701
    [No Abstract]   [Full Text] [Related]  

  • 9. [New sequential preparations for oral contraception. (Binordiol, Fysioquens and Sequilarum)].
    Obel EB
    Ugeskr Laeger; 1976 Jun; 138(26):1590-2. PubMed ID: 951765
    [No Abstract]   [Full Text] [Related]  

  • 10. [Controlled studies on the oral administration of progestagens, an antiestrogen and vitamin B6 in the treatment of mastodynias].
    Colin C
    Rev Med Brux; 1982 Nov; 3(9):605-9. PubMed ID: 6819627
    [No Abstract]   [Full Text] [Related]  

  • 11. [Follow-up observation of the so-called normophasic method of hormonal contraception].
    Fritzsche H; Möller R; Hempel E; Klinger G
    Z Arztl Fortbild (Jena); 1979 Feb; 73(3):113-4. PubMed ID: 373272
    [No Abstract]   [Full Text] [Related]  

  • 12. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Contraception; 1998 May; 57(5):315-24. PubMed ID: 9673838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of triphasic oral contraceptives in a continuous use regimen.
    Shulman LP
    Contraception; 2005 Aug; 72(2):105-10. PubMed ID: 16022848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptives and the risk of venous thrombosis.
    Vandenbroucke JP; Rosing J; Bloemenkamp KW; Middeldorp S; Helmerhorst FM; Bouma BN; Rosendaal FR
    N Engl J Med; 2001 May; 344(20):1527-35. PubMed ID: 11357157
    [No Abstract]   [Full Text] [Related]  

  • 16. [Serum level of thyroxin-binding globulin under oral contraception (author's transl)].
    Medau HJ; Rauskolb R
    Klin Wochenschr; 1975 Aug; 53(15):727-9. PubMed ID: 1219185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives.
    Wiegratz I; Kuhl H
    Treat Endocrinol; 2002; 1(6):372-86. PubMed ID: 15832490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changed routines in connection with first prescription of oral contraceptives. Lower risk of venous thromboembolism with levonorgestrel preparations].
    Milsom I; Odlind V; von Schoultz B; Ostlund I; Persson E
    Lakartidningen; 2002 Jan; 99(1-2):10-2, 15. PubMed ID: 11871161
    [No Abstract]   [Full Text] [Related]  

  • 19. Endometrial carcinoma and oral contraceptive agents.
    Cohen CJ; Deppe G
    Obstet Gynecol; 1977 Apr; 49(4):390-2. PubMed ID: 193073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestational potency of oral contraceptives.
    Dickey RP; Stone SC
    Obstet Gynecol; 1976 Jan; 47(1):106-12. PubMed ID: 1246375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.